We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our
Cookie Policy
.
Accept
Label
Search
SKIP TO CONTENT
SKIP NAVIGATION
Drug News
Trending
Commercial Operations
GMPs
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Device News
Trending
Commercial Operations
FDA Enforcement Actions
Inspections and Audits
Postmarket Safety
Quality
Regulatory Affairs
Research and Development
Submissions and Approvals
FDAnews
Books
FDAnews Books Library
Drug Books
Device Books
Training/Events
Webinar Training Pass
Events
Webinar Recordings
Resources
Form 483s Database
FDA Approved Drugs
CenterWatch
WCG Clinical
Sign In
Create Account
Sign Out
My Account
Home
»
Authors
» Jose E. Melendez
Jose E. Melendez
Products
PRODUCTS
Intas Pharmaceuticals Ltd.
Justin A. Boyd
,
Jose E. Melendez
, and
Pratik S. Upadhyay
Price:
$117.00
View
Janssen Cilag Manufacturing, LLC
Miguel A. Martinez
,
Jose E. Melendez
, and
Marian E. Ramirez
Price:
$117.00
View
Pfizer Healthcare India Pvt., Ltd.
Jose E. Melendez
Price:
$117.00
View
Mylan Laboratories Ltd.
Jose E. Melendez
Price:
$117.00
View
Mylan Laboratories Ltd.
Kellia N. Hicks
and
Jose E. Melendez
Price:
$117.00
View
Amgen Manufacturing Ltd.
Jennifer Lalama
,
Jose E. Melendez
, and
Adaliz Santaliz-Cruz
Price:
$117.00
View
Gador S.A.
Jose E. Melendez
Price:
$117.00
View
Aurobindo Pharma Ltd.
Walden H. Lee
,
Jose E. Melendez
, and
Linda F. Murphy
Price:
$117.00
View
Baxter Healthcare Corp.
Laurimer Kuilan-Torres
,
Miguel A. Martinez
, and
Jose E. Melendez
Price:
$117.00
View
MSD International GmbH
Jose E. Melendez
Price:
$117.00
View
View All Products by Jose E. Melendez
Upcoming Events
21
Oct
MAGI@home Clinical Research Conference 2024
Featured Products
From QSR to QMSR: Meeting FDA’s New Requirements
FDA Oversight of Laboratory-Developed Tests — The Impact of the Final Rule
Featured Stories
Risk of 10 Obesity-Driven Cancers Reduced by GLP-1s, Study Says
Three Device Areas Added to CDRH’s Device-Advancing TAP Program
Third Alzheimer’s Drug Gets FDA Approval, Just as Diagnostic Criteria Expand
Draft Guidance Covers Using URRAs in Combo Product Applications
The Revised ICH E8:
A Guide to New Clinical Trial Requirements
Learn More
